Holen Sie sich die Stockscreener-App
122.05
1.89%
2.26
Handel nachbörslich:
122.10
0.05
+0.04%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$119.79
Offen:
$119.82
24-Stunden-Volumen:
8.19M
Relative Volume:
1.20
Marktkapitalisierung:
$151.44B
Einnahmen:
$29.04B
Nettoeinkommen (Verlust:
$8.11B
KGV:
18.92
EPS:
6.4525
Netto-Cashflow:
$9.67B
1W Leistung:
+1.31%
1M Leistung:
+8.31%
6M Leistung:
+17.72%
1J Leistung:
+36.35%
1-Tages-Spanne:
$119.10
$122.31
1-Wochen-Bereich:
$114.02
$122.31
52-Wochen-Spanne:
$86.08
$124.61
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Vergleichen Sie GILD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
122.05 | 148.78B | 29.04B | 8.11B | 9.67B | 6.4525 |
|
LLY
Lilly Eli Co
|
896.53 | 772.28B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
186.26 | 455.04B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
211.96 | 385.18B | 59.64B | 2.37B | 18.24B | 1.331 |
|
NVS
Novartis Ag Adr
|
123.86 | 237.53B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
82.49 | 214.76B | 63.99B | 19.05B | 14.72B | 7.5596 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead Sciences, Inc. (GILD) Stock Forecasts - Yahoo! Finance Canada
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Applying chart zones and confluence areas to Gilead Sciences Inc.July 2025 Trade Ideas & Long-Term Growth Portfolio Plans - newser.com
Real time alert setup for Gilead Sciences Inc. performance2025 Top Decliners & Step-by-Step Swing Trade Plans - newser.com
Gilead Sciences, Inc. (GILD.NE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025 - The Joplin Globe
Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting - GlobeNewswire Inc.
Bernstein reiterates Gilead stock rating at Outperform on strong HIV core - Investing.com Nigeria
iA Global Asset Management Inc. Acquires 6,297 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Stake Decreased by Hunter Associates Investment Management LLC - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by South Dakota Investment Council - MarketBeat
2,128 Shares in Gilead Sciences, Inc. $GILD Purchased by Elm Partners Management LLC - MarketBeat
Spire Wealth Management Cuts Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
What candlestick patterns are forming on Gilead Sciences Inc.Trade Signal Summary & Risk Adjusted Buy and Sell Alerts - newser.com
Is Gilead Sciences Inc. stock cheap at current valuationJobs Report & Accurate Technical Buy Alerts - newser.com
Longbow Finance SA Purchases 9,390 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Syverson Strege & Co Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
NWK Group Inc. Has $7.33 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by Assetmark Inc. - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2025 Earnings Call Transcript - Insider Monkey
Gilead Sciences, Inc. (GILD) Analyst insights, Price targets and Recommendations - Yahoo! Finance Australia
Gilead Sciences, Inc. (GILD) Stock forecasts - Yahoo! Finance UK
Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Gilead Sciences (GILD) Margin Recovery Reinforces Bullish Narrative With 6,336% Earnings Growth - Sahm
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $105.00 at Royal Bank Of Canada - MarketBeat
Gilead Sciences' (GILD) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Morgan Stanley Boosts Gilead Sciences (NASDAQ:GILD) Price Target to $147.00 - MarketBeat
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $145.00 - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Plans $0.79 Quarterly Dividend - MarketBeat
Gilead Sciences (NASDAQ:GILD) Given New $110.00 Price Target at The Goldman Sachs Group - MarketBeat
Gilead Sciences (NASDAQ:GILD) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Wells Fargo Maintains Gilead Sciences (GILD) Overweight Recommendation - Nasdaq
Fisher Funds Management LTD Reduces Position in Gilead Sciences, Inc. $GILD - MarketBeat
Atria Investments Inc Purchases 14,392 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Price momentum metrics for Gilead Sciences Inc. explainedTrade Analysis Report & Proven Capital Preservation Methods - newser.com
JP Morgan Raises Gilead Sciences (GILD) Price Target to $150 | G - GuruFocus
Gilead Sciences (NASDAQ:GILD) Posts Quarterly Earnings Results - MarketBeat
Gilead Sciences (GILD) Profit Margin Surge Reinforces Bullish Narratives on Operational Turnaround - Yahoo! Finance Singapore
Gilead Sciences’ Earnings Call Highlights Growth and Optimism - TipRanks
Needham Reiterates Gilead Sciences (GILD) Buy Recommendation - Nasdaq
Gilead Sciences (NASDAQ:GILD) Updates FY 2025 Earnings Guidance - MarketBeat
Gilead Stock Reverses; Why Its New HIV Shot Looks Better - Investor's Business Daily
Research Alert: CFRA Keeps Buy Rating On Shares Of Gilead Sciences, Inc. - 富途牛牛
Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026 - Benzinga
RBC Capital Maintains Gilead Sciences (GILD) Rating, Raises Pric - GuruFocus
Gilead's long-acting PrEP Yeztugo takes off while cell therapy declines continue to haunt sales - Fierce Pharma
Gilead Sciences: Strong Performance and Future Potential Drive Buy Rating - TipRanks
Gilead's Cell Therapy Portfolio Slumps in Q3, but Firm Still Optimistic About In Vivo Opportunities - Precision Medicine Online
GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow - TradingView
HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead - Enidnews.com
Does Gilead Sciences Offer Strong Value After Breakthroughs in Antiviral Treatments? - simplywall.st
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.71%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):